Lv4
500 积分 2023-10-20 加入
Long-Term Survival and Gradual Recovery of B Cells in Patients with Refractory Large B Cell Lymphoma Treated with Axicabtagene Ciloleucel (Axi-Cel)
16小时前
求助中
Is there a role for immunomodulatory drugs in the treatment of mantle cell lymphoma?
27天前
已完结
Maintenance low-dose fixed duration lenalidomide and rituximab following bendamustine and rituximab induction in previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma
28天前
已完结
Maintenance low-dose fixed duration lenalidomide and rituximab following bendamustine and rituximab induction in previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma
28天前
已关闭
Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study
29天前
已完结
Maintenance low-dose fixed duration lenalidomide and rituximab following bendamustine and rituximab induction in previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma
29天前
已完结
Maintenance low-dose fixed duration lenalidomide and rituximab following bendamustine and rituximab induction in previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma
29天前
已关闭
Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study
1个月前
已完结
Belantamab Mafodotin, Bortezomib, and Dexamethasone vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 DREAMM-7 Tria
1个月前
已关闭
Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma
1个月前
已完结
皖公网安备34019202002308
